Search Results - Boyu Hu

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Maritime Spectrum Sensing Based on Cyclostationary Features and Convolutional Neural Networks by Xuan Geng, Boyu Hu

    Published in Entropy (2025-07-01)
    Get full text
    Article


  2. 2

    Ultra‐low dose radiation therapy for primary cutaneous indolent B‐cell lymphomas by Shalini Kasera, Christopher R. Weil, David Wada, Marianne Bowling, Boyu Hu, David K. Gaffney, Amit Maity, Randa Tao

    Published in JEADV Clinical Practice (2024-09-01)
    Get full text
    Article


  3. 3

    Secondary malignancies in non‐Hodgkin lymphoma survivors: 40 years of follow‐up assessed by treatment modality by Matthew W. Parsons, Calvin Rock, Jonathan J. Chipman, Harsh R. Shah, Boyu Hu, Deborah M. Stephens, Randa Tao, Jonathan D. Tward, David K. Gaffney

    Published in Cancer Medicine (2023-02-01)
    Get full text
    Article


  4. 4

    P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe r... by Georg Schett, Fan Wu, Nikolay Delev, Ruth Salmon, Jerill Thorpe, Amitkumar Mehta, Tatyana Feldman, Jeremy Abramson, Boyu Hu, Fabien Müller, Ashley Koegel, Divya Varun, Alison Maier, David Kugler, Matthew Westoby

    Published in Lupus Science and Medicine (2024-03-01)
    Article


  5. 5

    P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma by Harsh Shah, Victoria Vardell, Erin Zacholski, Amanda Fegley, Kalub Fedak, Suchitra Sundaram, Sridevi Rajeeve, Gaurav Goyal, Haris Hatic, Pallawi Torka, Sheeba Ba Aqeel, Azra Borogovac, Kira Macdougall, Shalin Kothari, Anna Kress, Dipenkumar Modi, Elizabeth Travers, Nitin Chilakamarri, Elizabeth Brem, Deborah M. Stephens, Boyu Hu, Lindsey Fitzgerlad, Charlotte Wagner, Daniel Ermann

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  6. 6

    Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outc... by Charlotte B. Wagner, Ken Boucher, Adrienne Nedved, Ivana N. Micallef, Sanjal Desai, Haris Hatic, Gaurav Goyal, Erin Zacholski, Amanda Fegley, Audrey M. Sigmund, David A. Bond, Courtney Samuels, Manali K. Kamdar, Sheeba Ba Aqeel, Pallawi Torka, Kira MacDougall, Azra Borogovac, Sridevi Rajeeve, Suchitra Sundaram, Kalub Fedak, Dipenkumar Modi, Elizabeth Travers, Sabarish Ayyappan, Nitin Chilakamarri, Elizabeth A. Brem, Daniel A. Ermann, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens, Harsh Shah

    Published in Haematologica (2023-04-01)
    Get full text
    Article


  7. 7

    Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers by Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, Ning Dong, David Qualls, Behzad Amoozgar, Brad Kahl, John Baird, Pavan Challa, Scott F Huntington, Jennifer Santos, Steven Bair, Mayur Narkhede, Shuning Li, Zachary Frosch, Carrie Ho, Stephen D Smith, Allison Winter, Daniel Landsburg, Fateeha Furqan, Mehdi Hamadani, Katelin Baird, Jason Romancik, Hanan Alharthy, Jennie Law, Leyla Bojanini, Ranjana Advani, Boyu Hu, Patrick Connor Johnson, Natalie S. Grover, Mwanasha Merril, Jennifer L. Crombie, Nazila Shafagati, Cole Sterling, Loretta J. Nastoupil, Narendranath Epperla, Emily C Ayers

    Published in Haematologica (2024-11-01)
    Get full text
    Article


Search Tools: